Cardiff Oncology, Inc. · NASDAQ:CRDF
Cardiff Oncology — Investor Presentation (October 2022)
78 slides from Cardiff Oncology's investor presentation, Oct 3, 2022
Slide 1: Company Overview: The Onvansertib Opportunity
Company Overview The Onvansertib Opportunity
Slide 2: Forward-looking statements
Forward-looking statements CERTAIN STATEMENTS IN THIS PRESENTATION ARE FORWARD-LOOKING within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other sim
Slide 3: Many chemotherapy agents damage a cancer cell's ability to replicate
Many chemotherapy agents damage a cancer cell's ability to replicate DNA Further synthesis cell growth Initial Mitosis cell growth (cell division)
Slide 4: Cancers thrive because they prioritize DNA replication and cell division
Cancers thrive because they prioritize DNA replication and cell division
Slide 5: PLK1 is a master regulator of genome integrity during cell replication
PLK1 is a master regulator of genome integrity during cell replication DNA Further synthesis cell growth Initial Mitosis cell growth (cell division)
Slide 6: PLK1 plays multiple roles during cell cycle
G2 G1 M S PLK1 plays multiple roles during cell cycle S-Phase G2/M Checkpoint M-Phase
Slide 7: PLK1 plays multiple roles during cell cycle
G1 M S G2 PLK1 plays multiple roles during cell cycle S-Phase G2/M Checkpoint M-Phase
Slide 8: PLK1 plays multiple roles during cell cycle
G2 G1 S M PLK1 plays multiple roles during cell cycle S-Phase G2/M Checkpoint M-Phase
Slide 9: Onvansertib inhibits PLK1
PLK1 is a master regulator of genome integrity during cell replication ONVANSERTIB INHIBITS PLK1 onvansertib shuts down TOL PLK1's cell- HN preservation en mechanisms, enhancing the efficacy of cell- damaging cancer therapies
Slide 10: Onvansertib positions Cardiff Oncology to effectively target PLK1
Onvansertib positions Cardiff Oncology to effectively target PLK1 PROPERTIES SPECIFICITY * Small molecule Exquisitely specific for PLK1 * Oral dosing ENZYME ICso (wM) * 24-hour half-life =e 6605 F rr PLK2 >10 TOL PLK3 >10 HN N ao won on CK2 0.4 NHK FLT3 0.4 \ CDK1/CycB >10 fo} 42 otherkinases >10 an
Slide 11: What, Why, Where
Scarditt Oncology” WHAT Onvansertib has achieved WHY 9 Onvansertib works WHERE Cardiff Oncology can go
Slide 12: What Onvansertib has achieved
Oo 0 Cardiff Oncology” % ooo WHAT Onvansertib has achieved () WHY 9 Onvansertib works WHERE § Cardiff Oncology can go
Slide 13: 1st line / 2nd line, normal vs mutated
1st LINE 2nd LINENormal Mutated
Slide 14: 2nd line historical ORR
2nd LINE HISTORICAL ORR 5% 11.4% 13% *1st LINENormal Mutated
Slide 15: 2nd line, normal vs mutated
2nd LINE1st LINENormal Mutated
Slide 16: KRAS/NRAS Mutations in mCRC
KRAS/NRAS Mutations in mCRC1
Slide 17: KRAS/NRAS Mutations in mCRC
93% KRAS/NRAS Mutations in mCRC1
Slide 18: MOA: KRAS/NRAS Mutations in mCRC
MOA 2 1 KRAS/NRAS Mutations in mCRC1
Slide 19: Single arm trial design
28 DAY CYCLE ENROLLMENT CRITERIA SINGLE ARM TRIAL
Slide 20: Single arm trial design
28 DAY CYCLE ENROLLMENT CRITERIA SINGLE ARM TRIAL 1 2 3
Slide 21: Patients achieved a strong, durable response with onvansertib + SoC
Patients achieved a strong, durable response with onvansertib + SoC Best Radiographic Response® — all doses (as of July 25, 2022) % change in target lesions from baseline 1004 All ‘mm Complete Response © mm Partial Response mm Stable Disease Doses © Confirmed CR © Confirmed PR fmm Progressive Diseas
Slide 22: We observe initial PRs up to eight months on treatment
We observe initial PRs up to eight months on treatment & ce —— Swimmer plot* — all doses (as of July 25, 2022) ra S r “e 8 e 6 ‘° 8 ea Evaluable Patients — all doses 48 o 8 a © a . en 2 — 7 Time of initial PR 8 8 {1 OnFotow te % e 8-week scan 8 ce = On Treatment e ¢ go 16-week scan 3 SS © Confirmed
Slide 23: Response by KRAS variant
KRAS Variant CR+PR SD PD Total
Slide 24: Objective Response Rate for mCRC trial exceeds SoC over time
Objective Response Rate for mCRC trial exceeds SoC over time Onvansertib+SoC ORR over time RP2D [ey 42% mmm of 19 ALL DOSES m= 36% ALL DOSES 38% pag tt DOSES 35% 17 of 48t oo 3 Historical SoC* ORR Sof 14 34% RP2D 12 of 351 11.4% 13% = L 1 — _—— 2008 8913 17 Jan Apr Jul Oct Jan * 2008: Bennouna etal,
Slide 25: Progression Free Survival for mCRC trial exceeds SoC over time
Progression Free Survival for mCRC trial exceeds SoC over time Onvansertib+SoC mPFS -— as of July 25, 2022 ALL DOSES Historical SoC* mPFS (mo) ee 9.4 mot Ant Oace 8.2 mo — 45 ~ RP2D | i l = — . . 2008 2013 2017 Get Jan Apr Jul Oct Lancet Oncol 2013; 14: 2° e ca, 193; 2017: Cremolini et al,, Lancet O
Slide 26: Why Onvansertib works
Scaraitt Oncology WHAT Onvansertib has achieved (@) ele) do WHY 9 Onvansertib works @) WHERE § Cardiff Oncology can go
Slide 27: Onvansertib's safety profile
Onvansertib’s safety profile
Slide 28: KRAS hypersensitivity and synergy with chemo
S G2 G1 M KRAS HYPERSENSITIVITY1 SYNERGY WITH CHEMO MOA 1 MOA 2
Slide 29: KRAS hypersensitivity
KRAS HYPERSENSITIVITY1 MOA 1
Slide 30: Synergy with chemo
SYNERGY WITH CHEMOKRAS HYPERSENSITIVITY1 S G2 G1 M MOA 1 MOA 2
Slide 31: Tumor cell cycle: DNA replication phase
S G2 G1 M TUMOR CELL CYCLE DNA REPLICATION PHASE
Slide 32: Tumor cell cycle: cell growth phase
S G2 G1 M TUMOR CELL CYCLE DNA REPLICATION PHASE CELL GROWTH PHASE
Slide 33: Tumor cell cycle: cell growth phase
S G2 G1 M TUMOR CELL CYCLE CELL GROWTH PHASE
Slide 34: Tumor cell cycle: cell growth phase
S G2 G1 M TUMOR CELL CYCLE CELL GROWTH PHASE
Slide 35: Where Cardiff Oncology can go
WHAT 3 Onvansertib has achieved O WHY 9 Onvansertib works ie) ooo no WHERE (Cardiff Oncology can go @)
Slide 36: Goals 2023-2025
1 2 GOALS 2025 Q1 Q2 2023 2024 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
Slide 37: Demonstrate, Confirm, Position, Operate
DEMONSTRATE CONFIRM POSITION OPERATE
Slide 38: Trial design: day, cycle, enrollment criteria
28 DAY CYCLE ENROLLMENT CRITERIA
Slide 39: Endpoints and enrollment criteria
ENDPOINTS Primary Key Secondary Other Secondary ENROLLMENT CRITERIA
Slide 40: Investigator-initiated trials pipeline
Preclinical Ph1/2 Ph2/3 Investigator-initiated trials Combination with: Status Investigator
Slide 41: Breakthrough Growth Initiative: Pfizer summary terms
BREAKTHROUGH GROWTH INITIATIVE • • • Pfizer • • SUMMARY TERMS
Slide 42: Targets with and without oncogenic alterations
Targets with oncogenic alterations Targets without oncogenic alterations
Slide 43: We have multiple important catalysts over the next two years
We have multiple important catalysts over the next two years mPDAC TNBC mCRC data readout data readout randomized data readout SCLC data readout © ONSEMB LE 39 23 15 0 [J mCRC mPDAC TNBC_ SCLC 2L K/N-mut at 2Linvasive Salvage
Slide 44: At June 30, 2022, our financial position is robust
At June 30, 2022, our financial position is robust mPDAC TNBC mCRC data readout data readout randomized data readout SCLC data readout @ONSEMBLE mRC Clinical Til June 30, 2022 cash and investments’ $122.0M Net cash used in Operating Activities" (Rolling two-quarter period ending June 30, 2022) S15.2
Slide 45: KRAS-Mutated Metastatic Colorectal Cancer (mCRC)
KRAS-Mutated Metastatic Colorectal Cancer (mCRC)
Slide 46: Summary of onvansertib mCRC Ph1b/2 trial data over time
Summary of onvansertib mCRC Ph1b/2 trial data over time Data Cutoff Date Evaluable Patients ORR (CR+PR) Confirmed CR/PRs Duration of Response mPFS Disease control rate (CR+PR+SD) ASCO GI Jan 2021 Nov 1, 2020* All Doses 14 36% (5) 29% (4) 86% (12) KOL Event Sept 2021 July 2, 2021* All Doses RP2D 32 1
Slide 47: No major/unexpected toxicities
No major/unexpected toxicities GRADE TEAEs* 1 2 3 4 All • • • GRADE TEAEs* 1 2 3 4 All
Slide 48: Phase 1b/2 trial design
28 DAY CYCLE ENROLLMENT CRITERIA SINGLE ARM TRIAL PHASE 1b PHASE 2
Slide 49: Progression Free Survival for mCRC trial exceeds SoC over time
Progression Free Survival for mCRC trial exceeds SoC over time Progression free survival* — all doses (as of July 25, 2022) B 1.00 2 3 Historical SoC* mPFS (mo) > 0.75 | 5.6 3 5.7 a 5 0.50 [eo-ene a : H 2008 2013 2017 0.00 | Median PFS: 9.3 0 5 10 15 20 Months * mPES is interim data from an ongoing
Slide 50: Predictive response biomarker: KRAS mutant allelic frequency
Predictive response biomarker • • • % KRAS Mutant Allelic Frequency (MAF)*
Slide 51: Early Changes in KRAS MAF predicts clinical response
Early Changes in KRAS MAF predicts clinical response ORR (% mPFS (mo = (*) (mo) § 1.005 KRAS RESPONDERS > KRAS KRAS 5 RESPONDERS RESPONDERS 2 5 07 64% 12.6 mo 307s 14 of 22 = 4 8 KRAS NON-RESPONDERS ee 2 L KRAS — NON-RESPONDERS, 0.25 6.0 mo KRAS H NON-RESPONDERS 0.00 - 6.0 . 7 | 9 : : : | as 0 5 10
Slide 52: Historical reference PFS and OS
HISTORICAL REFERENCE 5.7 4.5 5.6 11.2 11.5 — PFS OS
Slide 53: Enrollment criteria and design stats
ENROLLMENT CRITERIA • • • • DESIGN STATS • • •
Slide 54: KRAS-Mutated mCRC Bevacizumab Subgroup Data
KRAS-Mutated Metastatic Colorectal Cancer Bevacizumab Subgroup Data
Slide 55: The trial's patient demographics reflect 2nd-4th line mCRC population
The trial’s patient demographics reflects 2™4 line mCRC population Enrollment* Number of Patients (n) Phase 1b, Dose Level 0 Onvansertib 12 mg/m? Phase 1b, Dose Level +1 Onvansertib 15 mg/m? Treated 6 6 Currently on treatment 0 0 Total Patients N=50 Median [range] or n (%) Age (years) 61 [35-83] Sex
Slide 56: Normal RAS vs mutated, 1st and 2nd line
Normal RAS Mutated 1st LINE 2nd LINE mCRC Ph1b/2 trial
Slide 57: Efficacy data from historical trials in mCRC
Normal RAS Mutated EFFICACY DATA FROM HISTORICAL TRIALS IN mCRC 2nd Line mOS (mo)1-22nd Line mPFS (mo)1-2 2nd LINE 2nd Line ORR3-6
Slide 58: Historical controls vs onvansertib Ph1b/2 data
Normal HISTORICAL CONTROLS VS ONVANSERTIB* Ph 1b/2 DATA 2nd Line mPFS (mo)1-2 2nd LINE 2nd Line ORR3-6 RAS Mutated
Slide 59: No single patient characteristic explains observed ORR difference
N= No (naïve) Yes (exposed) No single patient characteristic explains observed ORR difference
Slide 60: How should we respond to this observation?
No (naïve) Yes (exposed) How should we respond to this observation? ACTIONS OPPORTUNITY
Slide 61: Durability in Bev naive patients
All Doses RP2D Durability Bev naïve patients
Slide 62: Bev exposure in 1st line and best response
Bev exposure in 1st lineNo prior bev exposure (naïve) Best response of: CR/PR SD PD
Slide 63: We observe initial PRs up to eight months on treatment
We observe initial PRs up to eight months on treatment & = = = _* Swimmer plot* — all doses (as of July 25, 2022) 3 3 S 8 8 > oO e 8 e sg 8 » g ° Evaluable Patients — all doses: 48 3 ° = ° 8 3 : = 8 = (On Trial | On Follow Up All Bev Bev oe 8 On Treatment Time of initial PR patients naive exposed SS
Slide 64: Metastatic Pancreatic Adenocarcinoma (mPDAC)
Metastatic Pancreatic Adenocarcinoma (mPDAC)
Slide 65: mPDAC single arm trial design
14 DAY CYCLE ENROLLMENT CRITERIA SINGLE ARM TRIAL
Slide 66: mPDAC single arm trial design
14 DAY CYCLE ENROLLMENT CRITERIA SINGLE ARM TRIAL 1 2 3
Slide 67: mPDAC historical mPFS and response rate
14 DAY CYCLE ENROLLMENT CRITERIA SINGLE ARM TRIAL HISTORICAL mPFS* 3.1 mo HISTORICAL RESPONSE RATE* 7.7% ORR 20% ≥6 mo
Slide 68: Early data from our mPDAC trial data is encouraging
Early data from our mPDAC trial data is encouraging Swimmer plot* — as of August 30, 2022 Change in tumor size from baseline* fe) fe) [e) 2 fe) [e) oO 5 © 04-012 [o) (e) ‘@ 20 oO > pr eo a) ‘ 2 2 4 6 Months Ee O's ———__]_—__————or08 R= 05-014 o ¢$—_—»_____-e 05.009 0 2.5) 5.0, 7.5 Months 2) « -20 pr
Slide 69: Investigator-Initiated Trial: Triple Negative Breast Cancer (TNBC)
Investigator-Initiated Trial Triple Negative Breast Cancer (TNBC)
Slide 70: Onvansertib + paclitaxel is superior to single agent therapy
Onvansertib + paclitaxel is superior to single agent therapy TRIAL RATIONALE In vivo efficacy of onvansertib in combination with paclitaxel Tp53-Mutant SUM159 xenografts* The combination of onvansertib + paclitaxel = 1200 showed significant synergy = % 1000 a control (n=8) 9 800 S 600 paclitaxel (10
Slide 71: TNBC enrollment criteria and primary endpoints
− ENROLLMENT CRITERIA PRIMARY ENDPOINTS 28 DAY CYCLE
Slide 72: TNBC enrollment criteria and endpoints
ENROLLMENT CRITERIA 28 DAY CYCLE PRIMARY ENDPOINTS SECONDARY ENDPOINT −
Slide 73: Investigator-Initiated Trial: Small Cell Lung Cancer (SCLC)
Investigator-Initiated Trial Small Cell Lung Cancer (SCLC)
Slide 74: Onvansertib demonstrates single-agent activity in SCLC
Onvansertib demonstrates single-agent activity in SCLC TRIAL RATIONALE In vivo efficacy of onvansertib monotherapy (SCLC xenografts)* Onvansertib monotherapy _ CISPLATIN RESISTANT CISPLATIN SENSIVITVE showed significant tumor = 2000 2000 growth inhibition against S son platinum-sensitive and o ,, ;
Slide 75: SCLC enrollment criteria and endpoints
ENROLLMENT CRITERIA 21 DAY CYCLE PRIMARY ENDPOINT SECONDARY ENDPOINTS
Slide 76: PARPi Pre-Clinical Data
ooo . Ae OOO PARPi Pre-Clinical Data ele (2)
Slide 77: Onvansertib + PARP inhibitors
Onvansertib + PARP inhibitors
Slide 78: Onvansertib + PARP inhibitors: probability of survival
Onvansertib + PARP inhibitors* P ro b ab ili ty o f S ur vi va l
Cardiff Oncology — Investor Presentation (October 2022) on 6ix